Lemoxol

Ceftazidime, the active ingredient in Lemoxol, is a third-generation cephalosporin presented as a sterile powder for reconstitution for intramuscular and intravenous use. It treats severe bacterial infections in hospitalized patients, including pneumonia, urinary tract infections, and intra‑abdominal infections.

GNH USA supplies Lemoxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lemoxol (ceftazidime) is employed to combat serious bacterial infections across several organ systems.

- Hospital‑acquired pneumonia: provides bactericidal activity against Gram‑negative pathogens, including Pseudomonas. - Complicated urinary tract infection: eradicates resistant Enterobacteriaceae causing pyelonephritis. - Intra‑abdominal infection: treats polymicrobial infections following surgery or perforation. - Skin and soft‑tissue infection: effective for severe cellulitis and wound infections. - Febrile neutropenia: offers broad coverage for high‑risk immunocompromised patients.

Adverse reactions may occur with any antibiotic therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Injection site pain: discomfort at the site of administration. - Elevated liver enzymes: transient increase in transaminases. - Transient increase in BUN/creatinine: mild renal function changes.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening hypersensitivity. - Clostridioides difficile‑associated colitis: severe diarrhea with pseudomembranous colitis. - Neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: low platelet count leading to bleeding risk. - Seizures: especially in patients with renal impairment or high doses. - Stevens‑Johnson syndrome: rare severe skin reaction.

Careful assessment is required before initiating therapy.

- Renal impairment: dose adjustment may be required based on creatinine clearance. - Hepatic dysfunction: monitor liver function tests during treatment. - Allergy: avoid in patients with known hypersensitivity to cephalosporins or other β‑lactams. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concurrent nephrotoxic drugs: monitor renal function closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ceftazidime may interact with several concomitant medications.

Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity. - Loop diuretics: heightened potential for ototoxicity. - Live bacterial vaccines: reduced vaccine efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring coagulation monitoring. - Other β‑lactams: additive risk of seizures, especially in renal failure. - Probenecid: may raise ceftazidime plasma concentrations, necessitating dose review.